Saturday, November 15, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Positive Outlook on Beauty Health SKIN with Buy Rating and 5 Price Target

Elaine Mendonca by Elaine Mendonca
March 15, 2024
in Breaking News
0
Beauty Industry Markets and money
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

On March 15, 2024, analyst Linda Bolton Weiser from DA Davidson reiterated her positive outlook on Beauty Health (SKIN), giving it a Buy rating. She also set a price target of $5 for the stock.

This reaffirmation of confidence in Beauty Health comes amidst a dynamic market landscape, where the company’s innovative products and strong performance continue to attract investor interest.

Investors may want to keep an eye on Beauty Health as it navigates the ever-evolving beauty and health industry, poised for potential growth and success in the future.

SKIN Stock Plummets 10.12% on March 15, 2024: Investors Advised to Proceed with Caution

On March 15, 2024, SKIN stock experienced a significant drop in its price performance. According to data from CNN Money, SKIN is currently trading near the bottom of its 52-week range and below its 200-day simple moving average, indicating a bearish trend for the stock. The price of SKIN shares decreased by $0.43 since the market last closed, representing a 10.12% drop. In pre-market trading, the stock dropped an additional $0.03. Investors and analysts may be concerned about the recent price momentum of SKIN stock, suggesting underlying issues affecting the company’s performance. It is advisable for investors to conduct thorough research and analysis before making any decisions regarding SKIN stock and to consult with a financial advisor for valuable insights. Overall, the performance of SKIN stock on March 15, 2024, reflects a downward trend in price momentum, and investors should proceed with caution and closely monitor the stock for any further developments.

SKIN Stock Performance Review: Mixed Results for March 15, 2024

On March 15, 2024, SKIN stock experienced mixed performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was $397.99 million, showing an increase of 8.78% compared to the previous year. However, the total revenue remained flat since the last quarter at $96.80 million.

In terms of net income, SKIN reported a net loss of $100.12 million for the past year, which represents a significant decrease of 325.57% compared to the previous year. On the other hand, the net loss for the last quarter improved slightly to -$9.40 million, showing no change from the previous quarter.

Earnings per share (EPS) for SKIN stock were reported at -$0.76 for the past year, reflecting a decrease of 232.44% compared to the previous year. However, the EPS for the last quarter improved to -$0.07, showing an increase of 86.86% from the previous quarter.

Overall, SKIN stock’s performance on March 15, 2024, reflected a mixed picture with improvements in some areas such as EPS for the last quarter, while facing challenges in others such as net income for the past year. Investors will likely closely monitor the company’s financial performance in the coming quarters.

Tags: SKIN
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_ Investing in stocks

Analyst Matt Summerville Bullish on Alta Equipment Group with 22 Price Target

Technology Quantum computing Market Capitalization

Stifel Analyst Maintains Buy Rating on Adobe with Lowered Price Target

Finances (2)

Stifel Analyst Reaffirms Buy Rating and Raises Price Target for Align Technology

Recommended

Healthcare-IT-and-tech

Revolutionizing Healthcare Accessibility with the MGMini A Collaboration Between KORE and Medical Guardian

2 years ago
Pharmaceutical Market Capitalization

Novo Nordisk Exceeds Expectations with Strong Q4 Financial Results and Promising Outlook for 2024

2 years ago
BigBear.ai Stock

BigBear.ai Gains Momentum with Airport Security Breakthrough

2 months ago
Novo Nordisk Stock

Pharmaceutical Giant Faces Market Crosscurrents as Regulatory Wins Clash with Pricing Pressures

4 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Culp Stock Faces Critical Survival Test Amid Steep Declines

Inhibrx Biosciences Shares Surge on Clinical Breakthrough

Campbell Soup Faces Analyst Skepticism Despite Institutional Backing

Elys Game Technology Shares Approach Critical Juncture

Diginex’s Bold AI Acquisition Signals Strategic Pivot

Fuel Cell Titans: Ballard Power’s Financial Muscle Versus PowerCell’s Margin Excellence

Trending

Sunrise Realty Trust Stock
Dividends

Mixed Signals from Sunrise Realty Trust: Strong Earnings Mask Revenue Concerns

by Robert Sasse
November 15, 2025
0

Sunrise Realty Trust's third-quarter 2025 financial performance presents investors with a complex puzzle. The company delivered an...

Chiquita Stock

Chiquita Shares Face Existential Crisis as Legal and Market Pressures Mount

November 15, 2025
iShares iBonds 2025 Term High Yield and Income ETF Stock

Approaching Maturity: The Final Chapter for iShares’ 2025 High Yield ETF

November 15, 2025
Culp Stock

Culp Stock Faces Critical Survival Test Amid Steep Declines

November 15, 2025
Inhibrx Biosciences Stock

Inhibrx Biosciences Shares Surge on Clinical Breakthrough

November 15, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Mixed Signals from Sunrise Realty Trust: Strong Earnings Mask Revenue Concerns
  • Chiquita Shares Face Existential Crisis as Legal and Market Pressures Mount
  • Approaching Maturity: The Final Chapter for iShares’ 2025 High Yield ETF

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com